Cargando…

Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis

INTRODUCTION: Although recurrence rate among cases of resected pancreatic cancer are as high as 85%, an optimal treatment for recurrent pancreatic cancer (RePC) has not been established. Previous evidence regarding RePC is scarce, and randomised controlled trials (RCTs) are particularly lacking. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jong-chan, Ahn, Soyeon, Cho, In Kuk, Lee, Jongchan, Kim, Jaihwan, Hwang, Jin-Hyeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892773/ https://www.ncbi.nlm.nih.gov/pubmed/29632079 http://dx.doi.org/10.1136/bmjopen-2017-017249

Ejemplares similares

Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol
por: Lee, Jong-chan, et al.
Publicado: (2016)

Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator
por: Cho, In Kuk, et al.
Publicado: (2020)

Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer
por: Lee, Jongchan, et al.
Publicado: (2020)

Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
por: Jung, Jae Hyup, et al.
Publicado: (2022)

Early versus delayed initiation of adjuvant treatment for pancreatic cancer
por: Kim, Hyoung Woo, et al.
Publicado: (2017)

Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis
por: Jung, Kwangrok, et al.
Publicado: (2023)

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience
por: Lee, Jongchan, et al.
Publicado: (2018)

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2019)

Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy
por: Ahn, Soomin, et al.
Publicado: (2022)

Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer
por: Lee, Ho-Kyoung, et al.
Publicado: (2021)

Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells
por: Youn, Yuna, et al.
Publicado: (2020)

High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
por: Lee, Yoon Suk, et al.
Publicado: (2015)

Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer
por: Ahn, Jinwoo, et al.
Publicado: (2022)

Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2021)

Involvement of the NF-κB signaling pathway in proliferation and invasion inhibited by Zwint-1 deficiency in Pancreatic Cancer Cells
por: Kim, Jae Hyeong, et al.
Publicado: (2020)

Editorial: Improving surgical outcomes after pancreatic resection
por: Caputo, Damiano, et al.
Publicado: (2022)

Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
por: Shin, Dong Woo, et al.
Publicado: (2021)

Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
por: Jung, Jae Hyup, et al.
Publicado: (2020)

Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern
por: Kim, Hyoung Woo, et al.
Publicado: (2017)

Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma
por: Kim, Hyoung Woo, et al.
Publicado: (2015)

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Risk Factors for Gallstone Formation in Resected Gastric Cancer Patients
por: Paik, Kyu-hyun, et al.
Publicado: (2016)

Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma
por: Shin, Dong Woo, et al.
Publicado: (2022)

Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients
por: Hwang, In Kyeom, et al.
Publicado: (2015)

Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma
por: Sung, You-Na, et al.
Publicado: (2021)

NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer
por: Jung, Kwangrok, et al.
Publicado: (2022)

Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer
por: Li, Shengnan, et al.
Publicado: (2022)

Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
por: Ji, Xiaoqin, et al.
Publicado: (2022)

Intraoperative Radiation “Boost” to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report
por: Thomas, Tarita O., et al.
Publicado: (2018)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2020)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection
por: Huang, Yao, et al.
Publicado: (2021)

Repeated Awake Surgical Resection(s) for Recurrent Diffuse Low-Grade Gliomas: Why, When, and How to Reoperate?
por: Duffau, Hugues
Publicado: (2022)

A case report of surgical resection treatment for complete remission after chemotherapy for advanced pancreatic cancer
por: Zhang, Zhongyan, et al.
Publicado: (2023)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer
por: Hussien, Nervana, et al.
Publicado: (2022)

Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
por: Song, Byeong Geun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ohs9n4gr1c08okjl2gpob97lbh